Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $2.5 billion.

  • Haemonetics' Liabilities and Shareholders Equity fell 159.52% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.8 billion, marking a year-over-year increase of 54.15%. This contributed to the annual value of $2.5 billion for FY2025, which is 1163.04% up from last year.
  • According to the latest figures from Q4 2025, Haemonetics' Liabilities and Shareholders Equity is $2.5 billion, which was down 159.52% from $2.4 billion recorded in Q3 2025.
  • Haemonetics' Liabilities and Shareholders Equity's 5-year high stood at $2.5 billion during Q2 2024, with a 5-year trough of $1.8 billion in Q3 2021.
  • In the last 5 years, Haemonetics' Liabilities and Shareholders Equity had a median value of $2.0 billion in 2023 and averaged $2.1 billion.
  • As far as peak fluctuations go, Haemonetics' Liabilities and Shareholders Equity soared by 4362.79% in 2021, and later crashed by 328.95% in 2025.
  • Quarter analysis of 5 years shows Haemonetics' Liabilities and Shareholders Equity stood at $1.8 billion in 2021, then increased by 4.25% to $1.9 billion in 2022, then increased by 17.16% to $2.2 billion in 2023, then increased by 15.04% to $2.5 billion in 2024, then dropped by 1.6% to $2.5 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $2.5 billion for Q4 2025, versus $2.4 billion for Q3 2025 and $2.5 billion for Q2 2025.